Ikarian Capital’s Rein Therapeutics RNTX Stock Holding History

Ikarian Capital’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-144,616	Closed	-$752K	–	165
2022 Q2	$752K	Sell	144,616 -488	-0.3%	-$4.48K	0.14%	90
2022 Q1	$1.49M	Buy	145,104 +6,925	+5%	+$62.7K	0.2%	82
2021 Q4	$1.56M	Hold	138,179	–	–	0.23%	80
2021 Q3	$2.82M	Sell	138,179 -1,821	-1%	-$39.9K	0.2%	110
2021 Q2	$3.5M	Hold	140,000	–	–	0.28%	85
2021 Q1	$4M	Buy	+140,000	New	+$4.8M	0.13%	140

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ikarian Capital's RNTX Position: Q3 2022 in Review

Ikarian Capital sold out of Rein Therapeutics (RNTX) in Q3 2022, closing a stake of 144,616 shares — an estimated $752K sold.

Ikarian Capital first reported a position in RNTX in Q1 2021 and held it in 6 quarters. The position peaked at $4M in Q1 2021. 33 funds tracked by Wall St. Rank hold RNTX as of Q3 2022.

Ikarian Capital reported no remaining Rein Therapeutics position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 144,616 Rein Therapeutics shares in Q3 2022, an estimated $752K.
Ikarian Capital first reported a position in Rein Therapeutics in Q1 2021 and held it in 6 quarters.
Ikarian Capital's Rein Therapeutics position peaked at $4M in Q1 2021.
33 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.